5:24 PM
 | 
Jan 08, 2013
 |  BC Extra  |  Company News

Amplimmune grants Daiichi option for autoimmune product AMP-110

Amplimmune Inc. (Rockville, Md.) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110. The option is exercisable through the completion of a proof-of-concept (POC) Phase II...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >